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Abstract
Background: We sought to evaluate patients’ adherence to optimal pharmacotherapy as re-
commended by the European Society of Cardiology, together with the assessment of potential 
clinical determinants of medical non-compliance in a large cohort of patients after endoscopic 
atraumatic coronary artery bypassing (EACAB).
Methods: This cross sectional study was conducted in a group of 706 individuals who 
underwent EACAB between April 1998 and December 2010. Data covering current phar-
macological treatment with antiplatelet agents, beta-blockers (BB) (or heart rate lowering 
calcium channel blockers [CCB] in case of intolerance and/or poor efficacy of beta-blockade), 
angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor blockers [ARB]) and 
statins was acquired. Mean duration of observation after the surgery was 2132 ± 1313 days.
Results: Complete follow-up data has been obtained from 415 living patients (341 males). 
Amongst them, 353 (85%) received antiplatelet agents, while BB or CCB were routinely in-
gested by 349 (84%) patients. Statins were used by 310 (74.7%) individuals and 274 (66%) 
subjects took ACE inhibitors or ARB. Baseline demographic and clinical features, including 
major co-morbidities had no impact on patients’ compliance with all investigated medications. 
There was no clear association between adherence to treatment and risk of rehospitalization or 
occurrence of major cerebral and cardiovascular events.
Conclusions: EACAB patients’ compliance with pharmacotherapy guidelines is insufficient 
and is unrelated to demographic and clinical features of the subjects. Multidisciplinary appro-
ach involving health education, enhancement in prescription drug affordability and a better 
rapport between doctors and patients should be incorporated into clinical practice to overcome 
therapeutic disobedience. (Cardiol J 2013; 20, 6: 648–654)
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Introduction
Coronary surgery remains a gold standard of 
treatment for a vast majority of patients with pro-
ximal left anterior descending artery stenosis [1]. 
Minimally-invasive totally endoscopic atraumatic 
coronary artery bypassing (EACAB) represents 
a unique off-pump procedure aimed at minimizing 
surgical trauma. By design, this approach eventu-
ally introduced an era of patient-oriented cardiac 
surgery associated with lesser degree of postope-
rative pain, early implementation of rehabilitation, 
shortened in-hospital stay and improved quality of 
life in contrast to on-pump techniques requiring 
median sternotomy [2].
Despite overt benefits for patients, EACAB 
constitutes an ultimately challenging surgical 
technique with a steep learning curve. Since 
methods of surgical revascularization are reaching 
an immensely complex level, a question of patients’ 
adherence to concurrent therapy rises. Apart from 
lifestyle modification, pharmacological treatment 
remains a cornerstone of secondary prevention of 
coronary artery disease (CAD) [3]. Primary and 
secondary prevention is of utmost importance 
for the reduction of cardiovascular morbidity and 
mortality [4]. Lifelong administration of antiplatelet 
agents, beta-blockers (BB), angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin receptor 
antagonists and statins is thus strongly recommen-
ded by the European Society of Cardiology (ESC) 
guidelines [5]. Still, only half of the patients suf-
fering from chronic diseases in developed countries 
follow treatment recommendations [6].
High satisfaction rate reported in patients 
after EACAB [7] makes them, in theory, perfect 
candidates for the evaluation of individual deter-
minants of pharmacological compliance, as opposed 
to patients undergoing standard on-pump coronary 
artery bypass grafting (CABG) fraught with local 
and systemic complications. Previous reports have 
extensively dealt with socioeconomic and educa-
tional aspects of drug non-compliance [8–10], how-
ever, clinical characteristics of pharmacologically 
non-adherent individuals still remain vague. More 
to the point, no convincing data exists concerning 
secondary medical prevention in subjects after 
EACAB. Thus, the authors intended to conduct 
a diligent evaluation of patients’ adherence to op-
timal pharmacotherapy as established by the ESC 
guidelines, together with the assessment of poten-
tial clinical risk factors of medical non-compliance 
in a large cohort of cardiac surgery patients.
Methods
We performed an epidemiological, cross-
-sectional study. The study group comprised 706 
consecutive patients with single-vessel (76.5%) or 
multi-vessel (23.5%) CAD, who underwent EACAB 
between April 1998 and December 2010. Baseline 
demographic and clinical characteristics of the 
patients, including the presence of concomitant 
diseases, were obtained from hospital records. 
Charlson comorbidity index [11] was calculated. 
Post-operative pharmacological treatment was also 
assessed. All patients gave their written informed 
consent to participate in the study. The study was 
approved by local Ethics Committee and complies 
with the Declaration of Helsinki.
The follow-up investigation was performed 
between February and December 2011. Mean dura-
tion of follow-up was 2132 ± 1313 (median 1918.5, 
longest 4661) days. Data covering current pharma-
cological treatment with antiplatelet agents, BB 
(or heart rate lowering calcium channel blockers 
[CCB] in case of intolerance and/or poor efficacy 
of beta-blockade), ACE inhibitors or angiotensin 
receptor blockers (ARB) and statins was acquired 
by means of structured telephone interview. In 
case of no response or unknown phone number, 
a standardized questionnaire was sent by post. All 
patients were subsequently interviewed with re-
spect to rehospitalization and the occurrence of ma-
jor cardiac and cerebrovascular events (MACCE), 
which were defined as: myocardial infarction (MI), 
repeat revascularization, and stroke or transient 
ischemic attack (TIA). The number of deceased 
patients was verified with national registry of car-
diac surgery procedures.
Impact of baseline demographic and clinical 
features on adherence to secondary pharmaco-
logical prevention was assessed. Additionally, 
we evaluated patients’ prognosis with relation 
to their compliance with the recommended 
treatment.
Statistical analysis
Statistical analysis was performed using the 
MedCalc software (v11.0.1). Data is shown as 
mean and standard deviation for quantitative 
variables, and as relative values and percentage 
for qualitative variables. In-group differences in 
quantitative variables were tested using analysis of 
variance (for normally distributed variables) or the 
Kruskal-Wallis test (for non-normally distributed 
variables). Normality of the data distribution was 
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verified using the Shapiro-Wilk test. Chi-square 
test was used for qualitative variables. Odds ratios 
with 95% confidence intervals were calculated to 
evaluate basic determinants of patients’ compliance 
and its association with outcome. P < 0.05 was 
considered statistically significant.
Results
Patients’ characteristics
In a prospective observation 20 (2.8%) patients 
died. Complete follow-up data has been obtained 
from 415 living patients, 74 females and 341 ma-
les (study response rate 58.8%). Detailed patient 
characteristics are shown in Table 1. In survivors, 
a total of 98 (23.6%) cardiac and cerebrovascular 
events were noticed: 26 (6.3%) had MI, 11 (2.6%) 
underwent stroke or TIA and 61 (14.7%) had repe-
at revascularization (only percutaneous coronary 
interventions [PCI]).
Pharmacological treatment in a follow-up
The majority of patients received drug the-
rapy as recommended by the ESC [5]. 353 (85%) 
patients received antiplatelet agents (including ace-
tylsalicylic acid [ASA], clopidogrel or ticlopidine), 
while BB or CCB were routinely ingested by 349 
(84%) patients. Statins were used by 310 (74.7%) 
of the EACAB patients. Only 274 (66%) subjects 
took ACE inhibitors or ARB.
ASA/clopidogrel/ticlopidine
It was demonstrated that gender (p = 0.9), 
diabetes mellitus (p = 0.9), hypertension (p = 0.8), 
previous MI (p = 0.9) or PCI (p = 0.3), Charlson 
index (p = 0.4) and ejection fraction (EF) (p = 0.1) 
had no impact on ingestion of antiplatelet agents. 
Patients who did not use antiplatelet drugs were on 
average 5 years older compared to those who com-
plied with treatment (p = 0.007) (Table 2, Fig. 1A). 
But the mean time of follow-up of the patients 
who were treated with the agents was also shorter 
compared to patients not using these drugs (1400 
days vs. 1900 days, respectively; p = 0.01).
Patients who used antiplatelet agents less fre-
quently underwent rehospitalization (of any cause) 
compared to those who did not comply with treatment 
(49.7% vs. 66.1%; p = 0.02). In patients who received 
antiplatelet drugs MACCE were observed as frequen-
tly as in those who did not (18.8% vs. 20.4%; p = 0.9). 
MI was unrelated to subjects’ compliance with antipla-
telet drugs (6.6% vs. 4.8%; p = 0.8). Treatment with 
antiplatelet medications was positively associated with 
the fact of repeat revascularization (16.6% vs. 4.8%; 
p = 0.02). Stroke occurrence was not related with 
treatment with antiplatelet drugs (2.3% vs. 4.8%; 
p = 0.4) (Fig. 2A).
Beta-blockers/calcium channel blockers
Amongst baseline features, it was found that 
gender (p = 0.9), diabetes mellitus (p = 0.3), hy-
pertension (p = 0.8), previous MI (p = 0.8) or PCI 
Table 1. Baseline characteristics of the subjects.
Age [years] 59 ± 6
Male gender 341 (82.2%)
Body mass index (BMI) [kg/m2] 27.7 ± 3.8
BMI ≥ 25 kg/m2 317 (76.4%)
Charlson comorbidity index 
[points]
3 ± 1
Diabetes mellitus 73 (17.6%)
Previous MI 164 (39.5%)
Previous PCI 98 (23.6%)
Arterial hypertension 225 (54.2%)
Peripheral artery disease 8 (1.9%)
COPD 12 (2.9%)
Chronic renal failure 8 (1.9%)
Smoking habit 174 (42%)
LVEF [%] 54 ± 7
MI — myocardial infarction; PCI — percutaneous coronary 
intervention; COPD — chronic obstructive pulmonary disease; 
LVEF — left ventricular ejection fraction
Table 2. Impact of preoperative qualitative demographic and clinical variables on patients’ compliance 
in a follow-up.
Variable Antiplatelet agent BB/CCB ACEI/ARB Statin
Male gender 0.98 (0.47–2.06) 0.97 (0.48–1.98) 0.75 (0.44–1.28) 1.40 (0.74–2.65)
Diabetes 1.13 (0.52–2.44) 0.69 (0.34–1.37) 1.37 (0.75–2.48) 0.75 (0.41–1.37)
Previous MI 0.96 (0.55–1.67) 1.09 (0.63–1.87) 1.34 (0.88–2.04) 1.25 (0.79–1.99)
Previous PCI 1.52 (0.78–2.96) 0.77 (0.43–1.38) 0.96 (0.6–1.56) 1.79 (1.03–3.13)*
Arterial hypertension 0.92 (0.52–1.62) 0.93 (0.63–1.87) 0.97 (0.63–1.5) 0.92 (0.57–1.47)
Values are odds ratio with 95% confidence interval (in brackets), *p < 0.05; ACE — angiotensin-converting enzyme inhibitor;  
ARB — angiotensin receptor blockers; BB — beta-blocker; CCB — calcium channel blocker; other abbreviations as in Table 1
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(p = 0.4), Charlson index (p = 0.7), age of subjects 
(p = 0.06) and EF (p = 0.5) were not associated 
with treatment with BB or CCB (Table 2, Fig. 1B). 
The mean time of follow-up of the patients who 
were treated with the agents was slightly shorter 
compared to patients not using these drugs (1500 
days vs. 1900 days, respectively; p < 0.001).
Patients who ingested BB/CCB were rehospi-
talized as frequently as those who were not taking 
medications (50.8% vs. 59%; p = 0.3). MACCE 
were observed as frequently in patients who recei-
ved BB as in those who did not (19.8% vs. 22.6%; 
p = 0.8). MI was unrelated to subjects’ compliance 
with BB/CCB (7.0% in those who used vs. 3.0% in 
those who did not use; p = 0.3), as well as repeat 
revascularization (15.9% vs. 9.1%; p = 0.2). Stroke 
occurrence was not also associated with treatment 
with BB/CCB (2.3% vs. 4.5%; p = 0.5) (Fig. 2B).
ACE inhibitors/ARB
None of the investigated preoperative variab-
les correlated with treatment with ACE inhibitors: 
gender (p = 0.3), diabetes mellitus (p = 0.4), hy-
pertension (p = 0.9), previous MI (p = 0.2) or PCI 
(p = 0.7), Charlson index (p = 0.6), age (p = 0.7) 
and EF (p = 0.8) (Table 2, Fig. 1C). The follow-up 
duration also did not influence taking ACE inhibi-
tors/ARB in secondary prevention (p = 0.2).
There was no association between the fact of 
receiving ACE inhibitors/ARB and the fact of reho-
spitalization (54% vs. 48.6%; p = 0.3) or MACCE 
occurrence (21.4% vs. 17.6%; p = 0.4). MI was 
also unrelated to subjects’ compliance with ACE 
inhibitors/ARB (7% in those who used vs. 5% in 
those who did not use; p = 0.6), as well as repeat 
revascularization (16.5% vs. 11.4%; p = 0.2) and 
stroke/TIA (2.2% vs. 3.5%; p = 0.6) (Fig. 2C).
Figure 1. Impact of preoperative quantitative demographic and clinical variables on patients’ compliance in a follow-
-up; A. Antiplatelet agents; B. Beta-blockers/calcium channel blocker; C. Angiotensin-converting enzyme inhibitors 
(ACEI)/angiotensin receptor blockers (ARB); D. Statins; ASA — acetylsalicylic acid; ADP INH — ADP-receptor inhibitors.
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Statins
As far as baseline variables are concerned, 
gender (p = 0.4), diabetes (p = 0.4), hypertension 
(p = 0.8), history of MI (p = 0.4) and Charlson 
index (p = 0.3) were unrelated with treatment 
with statins. Patients with a history of PCI recei-
ved statins more frequently than those with no 
previous PCI (p = 0.03). Age of subject (p = 0.1), 
EF (p = 0.6) had no association with statins’ in-
gestion (Table 2, Fig. 1D). The follow-up duration 
was statistically significantly related with patients’ 
compliance with statins — it was shorter in those 
subjects who were taking statins (1570 days vs. 
2016 days in those who did not receive statins; 
p < 0.001).
Patients treated with statins less frequently 
underwent rehospitalization (48.1% vs. 64.4%; 
p = 0.005). In patients who received statins, 
MACCE were documented with similar frequency 
compared to those who did not receive them (18.9% 
vs. 24.7%; p = 0.3). MI occurrence was not asso-
ciated with patients’ compliance (5.5% vs. 8.6%; 
p = 0.4), as well as repeat revascularization 
(15.2% vs. 13.5%; p = 0.8) or stroke/TIA (2% vs. 
5%; p = 0.2) (Fig. 2D).
Discussion
The present study has investigated the asso-
ciation between patients’ compliance with recom-
mended pharmacological treatment and baseline 
clinical variables, and postoperative cardiovascular 
events in a large cohort of patients after EACAB. 
This analysis appears to be crucial because of the 
paucity of similar data in literature. The knowledge 
concerning clinical characteristics of potentially 
non-compliant individuals might help improve 
ingestion of recommended medications by means 
of actions devoted particularly to those subjects.
The implementation of pharmacotherapy after 
cardiac surgery is of great importance as it reduces 
mortality, morbidity, risk of rehospitalization and 
increases quality of life. We found that fulfillment 
of recommended secondary prevention guidelines 
was insufficient in relation to all groups of drugs 
we took into account. Similar results were obtained 
by several investigators [12–14]. In the retrospec-
tive study of Vermeer and Bajorek [12] in patients 
3 months after MI only 82% subjects used BB, 
86% had statin therapy and 79% received either 
ACE inhibitor or ARB. Worrisome results are given 
Figure 2. Association between pharmacotherapy and major cerebral and cardiovascular events (MACCE); A. Anti-
platelet agents; B. Beta-blockers/calcium channel blocker; C. Angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers; D. Statins; MI — myocardial infarction; re-PCI — repeat revascularization with percutaneous coro-
nary intervention; TIA — transient ischemic attack.
www.cardiologyjournal.org 653
Łukasz J. Krzych et al., Pharmacotherapy after EACAB
by Lee et al. [13] who underlined unsatisfactory 
compliance with pharmacological treatment 
3 months after acute coronary syndrome. Their 
study revealed that only 63.9% of patients were 
receiving BB, 62.6% ingested statins and 51.8% 
had ACE inhibitor/ARB therapy [13]. Moreover, 
Griffo et al. [14] revealed that 12 months after 
percutaneous revascularization 94% of individuals 
were taking antiplatelet agents, 87% statins, 80.7% 
BB and 81.1% received ACE inhibitors. Regardless 
of statistical variations, all the above-mentioned 
reports stay consistent and disconcerting.
In the light of current ESC recommendations 
[3, 5] underpinning the importance of 4-drug 
regimen in stable patients after acute coronary 
syndrome, the observed discrepancy between 
guidelines and real medical practice substantiates 
further investigation into the risk factors of non-
-compliance. One of them is inappropriate imple-
mentation of the guidelines by physicians who are 
responsible for postoperative pharmacotherapy. 
This problem was described by Fox et al. [15] 
who documented that only 92% of CABG patients 
were ordered ASA, 70% BB, 73% had statins and 
26% were prescribed ACE inhibitors at discharge. 
In a similar study it was shown that 92% of pa-
tients were recommended to take ASA, 79% BB, 
55% ACE inhibitor or ARB and 92% statins [16]. 
Additionally, this important gap between current 
guidelines on cardiovascular pharmacotherapy and 
every-day clinical practice was illustrated in terms 
of primary prevention in Spanish primary health 
care units [17].
Secondly, contraindications and side effects 
account only for small portion of drug cessation. 
They include hypotension after ACE inhibitors or 
ARB, bradycardia following BB administration, 
major bleeding caused by antiplatelet agents and 
myopathy after statins. Yet, none of the respon-
dents demonstrated any of the abovementioned 
symptoms.
Dosing time of certain pharmacologic agents 
is, beyond doubt, a key factor contributing to non-
-compliance. Statins, ACE inhibitors and ARB are 
frequently ingested before sleep and therefore 
patients tend to withdraw or forget their nocturnal 
medications, whereas the introduction of once-
-daily formulations has proven beneficial in terms 
of adherence to evidence-based therapies [10]. 
Furthermore, there are no fixed combinations on 
the market combining any of the 4 drug regimen 
analyzed in our study. It has been well documented 
that high number of pills corresponds with poor 
compliance. Frequent termination of crucial drugs 
revealed by our study may be partially triggered 
by financial limitations, especially among seniors, 
due to high prices of drugs for the chronically ill 
patients or lack of social support. Lack of continuity 
of pharmacotherapy due to poor relay of clinical 
data between specialists and general practitioners 
often results in alteration of therapy, since dischar-
ge summaries are not directly mailed to outpatient 
clinic in the setting of Polish healthcare system.
Patients’ self-confidence of being cured by 
a complex cardiac procedure, endorsed by rapid 
improvement of physical exertion tolerance, may 
also be an incentive to cessation of pharmacothe-
rapy or even failure to fill the prescription [18].
Last but not least, a potent demographic fea-
ture in the form of education cannot be neglected 
as it directly affects the level of awareness and 
commitment to overcome the disease. The idea 
of patients’ involvement in the process of therapy 
derives from the salutogenic model of health pro-
posed by Antonovsky, which pursues psychosocial 
determinants of medical condition [19]. Lifestyle 
modification is regarded as the most efficient way of 
dealing with modifiable cardiovascular risk factors. 
In line with these principles of health promotion, 
therapeutic non-adherence is widely recognized 
as a vital, yet often underestimated cardiovascular 
risk factor common for all populations [20].
Interestingly, we have revealed some associa-
tion between compliance and MACCE occurrence. 
The patients who experienced repeat revasculari-
zation with PCI more frequently used antiplatelet 
drugs, which can probably be attributed to more 
careful approach of attending physicians alert to 
severe complications, such as stent thrombosis. 
It is in line with current recommendation as the 
treatment reduces risk of stent occlusion and sub-
sequent risk of all cardiovascular events, including 
death which was confirmed in several studies [21]. 
Also, we found a correlation between ingestion 
of antiplatelet agents and BB, and the need for 
readmission. Compliant individual less frequently 
experienced hospitalization compared to patients 
indifferent to pharmacotherapy, hence we assume 
that pharmacological interventions help improve 
patients’ outcome and reduce costs for the health-
care system [21–26]. Although our study failed to 
demonstrate a statistically significant link between 
patients’ clinical features and drug compliance, we 
managed to denote considerable prevalence of the 
issue of therapeutic non-adherence and its clinical 
implications.
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Limitations of the study
Unfortunately this study has several draw-
backs that should be taken into account in data 
interpretation. Firstly, although with prospective 
follow-up, the study is cross-sectional in its design. 
Accordingly, we may not assess cause — effect 
relationship between medications which have been 
taken and the incidence of MACCE. As a result, we 
also did not adjudicate the influence of the follow-
-up duration on the results. Nonetheless, we per-
formed a sub-analysis of impact of follow-up time 
on the subjects’ amenability in which we tried to 
overcome this limitation to some extent. Secondly, 
as we interviewed about 60% of the cohort, this 
research may generate selection bias, as well as 
recall bias in remaining participants. Finally, we did 
not attempt at minimizing the effect of confounders 
as we hadn’t performed a multivariate analysis. 
However, we found only minor determinants of 
patients’ compliance so the implementation of 
regression model was rather impractical.
Conclusions
EACAB patients’ compliance with pharma-
cotherapy guidelines is rather insufficient with 
regard to current ESC recommendations. We 
conclude that drug non-adherence does not cor-
respond with demographic and clinical features of 
the subjects. For improvement, multidisciplinary 
approach including patients’ education, enhance-
ment in therapeutic rapport between doctors and 
patients, as well as improvement of healthcare sy-
stem should be incorporated into clinical practice.
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